Featured Research

from universities, journals, and other organizations

Strategies To Counteract Side Effects Of New MS Therapies

Date:
September 14, 2009
Source:
Ruhr-Universitaet-Bochum
Summary:
The drawback of new immunotherapies in multiple sclerosis (MS) include severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis. Researchers recently employed plasmapheresis to eliminate the active pharmaceutical agent and thus clear the virus from the brain.

The drawback of new immunotherapies in multiple sclerosis (MS) include severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis. Prof. Ralf Gold (RUB Clinic for Neurology, St. Josef Hospital) and Dr. Werner Wenning (Ortenau Clinic, Offenburg-Gengebach) employed plasmapheresis to eliminate the active pharmaceutical agent and thus clear the virus from the brain.

Related Articles


A report on their successful method of treatment has been published in the current edition of the New England Journal of Medicine.

Suppressing the destructive impact of leukocytes in MS

Natalizumab is a monoclonal antibody that has been approved for the treatment of severe RR‑MS (relapse remitting MS) in the EU since 2006. The antibody attaches to specific structures on the surface of white blood cells thus reducing their ability to attach to and pass through vascular wall into the inflamed tissue. The active agent thus suppresses the destructive effects of leukocytes that attack the myelin sheath, the insulating layer of nerve fibres. Leukocytes theoretically attack and destroy destructive foreign substances such as viruses or bacteria, thus the drawback of this medication is a decrease in the immune defense of the brain.

Unfulfilled hope: monotherapy is also not harmless

Clinical studies with Natalizumab led to progressive multifocal leukoencephalopathy (PML) in two MS patients. This severe brain infection is triggered by the JC virus found in about 80% of all adults. Normally the immune system does however control the virus. Less experienced physicians can easily mistake PML symptoms with an acute attack of MS. Prof. Gold explained that both study patients had also been administered the immune activating drug Interferon Beta, thus the hope that the monotherapy was relatively harmless had been realistic. Moreover, when the drug was approved at the beginning of summer 2006, the manufacturing company BiogenIdec had offered country-specific intensive preparatory seminars covering almost all precautionary and therapeutic measures. In July 2008, PML was diagnosed almost simultaneously in a German and Swedish MS patient, after 14 and 16 months of Natalizumab treatment respectively.

The strategies of treating the infection are the topic of the two studies that were simultaneously submitted for publication by the German and Swedish authors. The German patient was treated by Dr. Werner Wenning in Offenburg, and the therapy supervised by Prof. Gold in Bochum.

Plasmapheresis eliminates the active agent natalizumab

The treatment was targeted at re-establishing the patients own immune system to enable it to eliminate the JC virus. The physicians thus had to remove the active agent Natalizumab from the patient’s body. Natalizumab circulates within the body for a very long time, taking an average half—life of 16 days (before the concentration is reduced by about 50%). The researchers in Bochum and Offenburg thus decided to perform Plasmapheresis.

Subsequent measurements showed that the drug plasma level had dropped from 10,8 µg/ml to below 0,25 µg/ml within a week. In parallel a temporary improvement of the symptoms was observed. A secondary deterioration developed 4 weeks later, with increased motor deficits as well as clouding of consciousness. In this phase of the immune reconstruction inflammatory syndrome (IRIS), immune cells (cytotoxic lymphocytes) eliminate the virus in the brain. This leads to the destruction of the infected oligodendrocytes, supporting cells in the brain responsible for the insulation of the nerve cell connections. The patient required 4 weeks of intensive care, including artificial respiration and tube feeding, before he could be transferred for follow-up rehabilitation. The therapeutic measures have been described and discussed in detail in the manuscript.

Neurologist must know how to handle new side effects

Prof. Gold pointed out that new MS drugs unfortunately also have new side effects that can sometimes be fatal. Currently Natalizumab is the focal point of interest throughout the world, but that other new drugs, such as Alemtuzumab or anti-CD20 antibodies may soon follow. It is thus important that the neurologists are extremely well-informed about complications and the treatment thereof. In future, “therapeutic navigation” through modern immune therapies with escalation and de-escalation cycles according to the activity of the disease may be possible.


Story Source:

The above story is based on materials provided by Ruhr-Universitaet-Bochum. Note: Materials may be edited for content and length.


Journal Reference:

  1. Werner Wenning, Aiden Aghikia, Jörg Laubenberger, David B. Clifford, Peter F. Behrens, Andrew Chan, Ralf Gold. Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. New England Journal of Medicine, 2009; 361 (11): 1075 DOI: 10.1056/NEJMoa0810257

Cite This Page:

Ruhr-Universitaet-Bochum. "Strategies To Counteract Side Effects Of New MS Therapies." ScienceDaily. ScienceDaily, 14 September 2009. <www.sciencedaily.com/releases/2009/09/090910084145.htm>.
Ruhr-Universitaet-Bochum. (2009, September 14). Strategies To Counteract Side Effects Of New MS Therapies. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2009/09/090910084145.htm
Ruhr-Universitaet-Bochum. "Strategies To Counteract Side Effects Of New MS Therapies." ScienceDaily. www.sciencedaily.com/releases/2009/09/090910084145.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins